Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Osende, J. I.
Right arrow Articles by Egido, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Osende, J. I.
Right arrow Articles by Egido, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Nephrol Dial Transplant (2004) 19: 528-531
Nephrol Dial Transplant Vol. 19 No. 3 (c) ERA-EDTA 2004; all rights reserved

Editorial Comment

Statins to prevent cardiovascular events in hypertensive patients. The ASCOT-LLA study

Julio I. Osende2, Marta Ruiz-Ortega1, Luis Miguel Blanco-Colio1 and Jesus Egido1

1Renal and Vascular Research Laboratory, Fundación ‘Jiménez-Díaz’ (Autonoma University) and 2Cardiology Service, ‘Gregorio Marañón’ General University Hospital, Madrid, Spain

Correspondence and offprint requests to: Professor Jesús Egido, Renal and Vascular Research Laboratory, Fundación Jimenez-Diaz. Avda Reyes Católicos, 2, 28040 Madrid, Spain. Email: jegido@fjd.es

Keywords: hypertension; primary prevention; statins

The first 10% of the full text of this article appears below.



   Introduction
 
The recently published Lipid-Lowering Arm of the Anglo-Scandinavian Cardiac Outcomes Study Trial (ASCOT-LLA) [1] provides interesting evidence for the use of statins in hypertensive patients with average cholesterol levels and other cardiovascular risk factors. In this study, 19 342 hypertensive patients with at least three other cardiovascular risk factors were randomized to two antihypertensive regimes (amlodipine and/or perindopril vs atenolol and/or clorthalidone) and were planned to be followed for 5 years.

The LLA was comprised of those patients with baseline total cholesterol levels <=6.5 mmol/l (~260 mg/dl), who were also randomized to receive daily atorvastatin 10 mg vs placebo. A total of 10 305 patients entered in the LLA, which was stopped prematurely by the safety committee after a mean follow-up of only 3.3 years due to a significantly lower incidence of . . . [Full Text of this Article]



   Comparison of the ASCOT-LLA trial with other major clinical statin trials
 


   Mechanisms involved in the benefit of statin treatment in hypertensive patients
 


   Unresolved issues in the ASCOT-LLA trial
 

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?